Exchange: NASDAQ·Updated 02:12 PM EDT

RPRX Earnings

Latest Earnings Results: Q2 '26

Reported: Aug 05

Estimated EPS

$1.26

Reported EPS

$1.32

Surprise

+4.72%

Estimated Rev

$750.18M

Reported Rev

$773M

Surprise

+3.04%

• Reported GAAP EPS of $0.03 down -57.14% YoY • Reported revenue of $674M up 16.47% YoY • Royalty Pharma raised its full year 2026 guidance for Portfolio Receipts to between $3,400 million and $3,500 million, representing expected Royalty Receipts growth of 7% to 10% for Royalty Pharma.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Investor Presentation10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q3 '26
$1.17
--
--
N/A
Q2 '26
$1.26
$1.32
4.72%
BEAT
Q1 '26
$1.10
$1.30
17.31%
BEAT
Q4 '25
$1.29
$1.47
14.02%
BEAT
Q3 '25
$0.99
$1.17
18.08%
BEAT

Advertisement|Remove ads.